TY - JOUR
T1 - Personalised advanced therapies in parkinson’s disease
T2 - The role of non-motor symptoms profile
AU - Leta, Valentina
AU - Dafsari, Haidar S.
AU - Sauerbier, Anna
AU - Metta, Vinod
AU - Titova, Nataliya
AU - Timmermann, Lars
AU - Ashkan, Keyoumars
AU - Samuel, Michael
AU - Pekkonen, Eero
AU - Odin, Per
AU - Antonini, Angelo
AU - Martinez-Martin, Pablo
AU - Parry, Miriam
AU - Van Wamelen, Daniel J.
AU - Ray Chaudhuri, K.
PY - 2021/8
Y1 - 2021/8
N2 - Device-aided therapies, including levodopa-carbidopa intestinal gel infusion, apomorphine subcutaneous infusion, and deep brain stimulation, are available in many countries for the management of the advanced stage of Parkinson’s disease (PD). Currently, selection of device-aided therapies is mainly focused on patients’ motor profile while non-motor symptoms play a role limited to being regarded as possible exclusion criteria in the decision-making process for the delivery and sustenance of a successful treatment. Differential beneficial effects on specific non-motor symptoms of the currently available device-aided therapies for PD are emerging and these could hold relevant clinical implications. In this viewpoint, we suggest that specific non-motor symptoms could be used as an additional anchor to motor symptoms and not merely as exclusion criteria to deliver bespoke and patient-specific personalised therapy for advanced PD.
AB - Device-aided therapies, including levodopa-carbidopa intestinal gel infusion, apomorphine subcutaneous infusion, and deep brain stimulation, are available in many countries for the management of the advanced stage of Parkinson’s disease (PD). Currently, selection of device-aided therapies is mainly focused on patients’ motor profile while non-motor symptoms play a role limited to being regarded as possible exclusion criteria in the decision-making process for the delivery and sustenance of a successful treatment. Differential beneficial effects on specific non-motor symptoms of the currently available device-aided therapies for PD are emerging and these could hold relevant clinical implications. In this viewpoint, we suggest that specific non-motor symptoms could be used as an additional anchor to motor symptoms and not merely as exclusion criteria to deliver bespoke and patient-specific personalised therapy for advanced PD.
KW - Apomorphine
KW - Deep brain stimulation
KW - Device-aided therapies
KW - Levodopa-carbidopa intestinal gel
KW - Non-motor symptoms
KW - Parkinson’s disease
KW - Personalised medicine
U2 - 10.3390/jpm11080773
DO - 10.3390/jpm11080773
M3 - Article
C2 - 34442417
AN - SCOPUS:85113773139
SN - 2075-4426
VL - 11
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
IS - 8
M1 - 773
ER -